DNA X terminates $500M equity line with Chardan Capital Markets

DNA X, Inc.

Terminated ChEF Purchase Agreement with Chardan Capital Markets, effective May 28, 2026.
Original agreement committed Chardan to purchase up to $500M of common stock.
Registration Rights Agreement also terminated.
No replacement financing disclosed.

item 1.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

DNA X, Inc. terminated Registration Rights Agreement with Chardan Capital Markets LLC (effective 2026-05-28).

Action: termination
Counterparty: Chardan Capital Markets LLC
Effective: 2026-05-28

Exact text from the filing

On May 29, 2026, the Company and Chardan entered into a letter agreement pursuant to which they agreed, among other things, to terminate, effective as of 5:00 p.m., New York City time, on May 28, 2026, the ChEF Agreement and Registration Rights Agreement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

DNA X, Inc. terminated ChEF Purchase Agreement with Chardan Capital Markets LLC valued at up to $500 million (effective 2026-05-28).

Action: termination
Agreement: equity purchase
Counterparty: Chardan Capital Markets LLC
Value: up to $500 million
Effective: 2026-05-28

Exact text from the filing

On May 29, 2026, the Company and Chardan entered into a letter agreement pursuant to which they agreed, among other things, to terminate, effective as of 5:00 p.m., New York City time, on May 28, 2026, the ChEF Agreement and Registration Rights Agreement.

View on SEC.gov

802 material agreements filed in the last 30 days. Browse all material agreements →

DNA X, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-027295

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.